[{"orgOrder":0,"company":"SK Pharmteco","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Nadofaragene Firadenovec","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"SK Pharmteco","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"SK Pharmteco \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"SK Pharmteco \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"SK Pharmteco","sponsor":"Rznomics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SK Pharmteco","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SK Pharmteco \/ Rznomics","highestDevelopmentStatusID":"14","companyTruncated":"SK Pharmteco \/ Rznomics"}]

Find Clinical Drug Pipeline Developments & Deals by SK Pharmteco

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The collaboration between SK and Rznomics to develop and commercialize multiple gene therapy products & to enable a smooth transition from clinical to full-scale commercial manufacturing.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          August 05, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery

                          Sponsor : Rznomics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The agreement aims to scale manufacturing for Adstiladrin (nadofaragene firadenovec), an intravesical non-replicating gene therapy approved for BCG-unresponsive non-muscle invasive bladder cancer.

                          Brand Name : Adstiladrin

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 18, 2024

                          Lead Product(s) : Nadofaragene Firadenovec

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Ferring Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank